Abeona (NASDAQ: ABEO) CCO granted 76,621 shares, sells 12,610 for taxes

Rhea-AI Filing Summary

Abeona Therapeutics Chief Commercial Officer Vasanthavada Madhav reported a new stock grant and a related share sale. On January 20, 2026, he received 76,621 shares of restricted common stock at $0.00, which will vest in three equal parts on January 20, 2027, January 20, 2028, and January 20, 2029. On January 22, 2026, he sold 12,610 shares of common stock at a weighted average price of $5.2861 per share to cover tax obligations from restricted stock vesting. After these transactions, he directly beneficially owned 318,619 shares of Abeona common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vasanthavada Madhav

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		A		76,621(1)	A	$0.00	331,229	D
Common Stock	01/22/2026		S(2)		12,610	D	$5.2861(3)	318,619	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock will vest one-third on each of January 20, 2027, January 20, 2028, and January 20, 2029

2. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.28 to $5.35 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Joseph Vazzano, as Attorney-in-fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ABEO Chief Commercial Officer Vasanthavada Madhav report?

He reported receiving 76,621 shares of restricted common stock on January 20, 2026, and selling 12,610 shares of common stock on January 22, 2026.

How will the new ABEO restricted stock grant to the CCO vest?

The 76,621 restricted shares will vest one-third on each of January 20, 2027, January 20, 2028, and January 20, 2029.

Why did the ABEO insider sell 12,610 shares of common stock?

The filing states that the sale of 12,610 shares was made to cover tax obligations associated with the vesting of restricted stock awards.

What price did the ABEO shares sell for in the insider tax-related sale?

The reported weighted average sale price was $5.2861 per share, with individual trades ranging from $5.28 to $5.35 per share.

How many ABEO shares does the CCO own after these transactions?

Following the reported grant and sale, Vasanthavada Madhav directly beneficially owned 318,619 shares of Abeona Therapeutics common stock.

What is Vasanthavada Madhav’s role at Abeona Therapeutics (ABEO)?

He is the Chief Commercial Officer of Abeona Therapeutics, as indicated in the insider reporting information.